Specialty sheet and rollstock: PreservaPak™ high-barrier technologies help preserve product freshness and extend shelf life for packaged foods, and raise the performance of sterile medical device packaging.

As hospitals implement robust cleaning protocols designed to battle healthcare associated infections, medical devices are subjected to various types of disinfectants at different concentrations and frequency of use.

PolyOne developed an ultra-soft version of its GLS™ TPE (thermoplastic elastomer) approved for food contact and medical applications, and included non-toxic PolyOne colorants. 

Abernathy Retired Chairman and Chief Executive Officer of Halyard Health, Inc., a medical technology company that focuses on eliminating pain, speeding recovery, and preventing infection for healthcare providers and patients worldwide. Green served as Otis’ Vice President, Transformation and Chief Digital Officer. Rockwell Automation”), a global leader in industrial automation and digital transformation.

Versaflex HC - Syringe Plunger - English SYRINGE MANUFACTURER D I S P O S A B L E S Y R I N G E P L U N G E R • USP VI and ISO 10993-4,5 compliant • Sterilize by gamma & EtO • Long-term sealing performance • Low coefficient of friction (COF) • Consistent performance across barrel sizes • Provided a formulated solution that met rigorous medical application requirements • Improved global supply continuity • Increased process efficiency by replacing previous thermoset material with TPE Versaflex™ HC 2110-57B KEY REQUIREMENTS WHY AVIENT?

Trilliant XR - CT and MRI Scanners MEDICAL DEVICE MANUFACTURER M R I A N D C T S C A N N E R S • Uniform shielding with no “hot spots” • X-ray shielding up to 140 KeV • Meet European Union’s Restriction of Hazardous Substances (RoHS) future compliance requirements • Provided a lead alternative solution that delivered improved geometric flexibility for more uniform radiation shielding • Lowered shielding component costs 30-50% by eliminating machining and assembly steps Trilliant™ XR Lead Replacement Thermoplastics KEY REQUIREMENTS WHY AVIENT?

• Formulated a solution that met rigorous medical application requirements • Leveraged global footprint to ensure supply continuity • Increased process efficiency by replacing previous thermoset material with TPE LEARN MORE https://www.avient.com/products/thermoplastic-elastomers/dynaflex-thermoplastic-elastomers

_2 /Ju n- 20 19 /V er si on 1 .0 Certificate Avient Colorants Singapore Pte Ltd 8 Third Chin Bee Road Jurong Industrial Estate 618684 Singapore Singapore Scope Administration, Site management, Manufacture, Laboratory, Procurement, Maintenance, infrastructure, Warehouse and Transport Normative base EN ISO 13485:2016 Medical devices – Quality Management System Reg. no. 45483 Validity 01. 03. 2022 – 28. 02. 2025 Issue 01. 03. 2022 A.Grisard, President SQS F.

Use of Non GAAP Measures Page 3 -150.00% -50.00% 50.00% 150.00% 250.00% 350.00% PolyOne S&P 500 Strategy and Execution Drive Results Page 4 All time closing high of $29.48 August 1, 2013 • 15 consecutive quarters of double digit EPS growth • 42% CAGR adjusted EPS expansion 2006-2012 • YTD stock price has increased 42% versus 20% growth in the S&P • 275% increase in market cap: $0.7b $2.6b since 2006 The World’s Premier Provider of Specialized Polymer Materials, Services & Solutions Four Pillar Strategy Page 5 PP&S 15% Specialty 60% Distribution 25% 0.12 0.27 0.21 0.13 0.68 0.82 1.00 2.50 $0.00 $0.25 $0.50 $0.75 $1.00 $1.25 $1.50 $1.75 $2.00 $2.25 $2.50 2006 2007 2008 2009 2010* 2011* 2012* 2015 Target Ad ju st ed E ar ni ng s P er S ha re Appliance 6% Building & Construction 13% Wire & Cable 9% Electrical & Electronics 4% Consumer 9% Packaging 18% Industrial 10% Misc. 5% HealthCare 9% Transportation 16% Textiles 1% United States 70% Europe 14% Canada 8% Asia 5% Latin America 3% 2012 Revenues: $4.0 Billion* End Markets* 2012 Revenues: $4.0 Billion* EPS Page 6 * Pro Forma includes FY2012 results for Spartech (11/03/12 YE) and Glasforms & excludes discontinued operations PolyOne At A Glance * Restated to exclude discontinued operations Old PolyOne Transformation *Operating Income excludes corporate charges and special items **Pro Forma results include Spartech and Glasforms acquisitions, Specialty Coatings reclass and excludes discontinued operations 2% 34% 43% 45% 60% 65- 75% 0% 20% 40% 60% 80% 100% 2005 2008 2010 2012 2012 PF** 2015 % o f O pe ra tin g In co m e* JV's PP&S Distribution Specialty Specialty OI $5M $46M $87M $114M $150M Target Mix Shift Highlights Specialty Transformation 2015 Target Page 7 2006 H1 2013 2015 Where we were Where we are Organic Consolidated Target 1) Operating Income % Specialty: Global Color, Additives & Inks 1.7% 12.7% 12.6% 12 – 16% Global Specialty Engineered Materials 1.1% 10.9% 9.2% 12 – 16% Designed Structures & Solutions — — 4.4% 8 – 10% Performance Products & Solutions 5.4% 8.1% 8.2% 9 – 12% Distribution 2.6% 6.1% 6.1% 6 – 7.5% 2) Specialty Platform % of Operating Income 6.0% 62% 65 – 75% 3) ROIC* (after-tax) 5.0% 9.4% 15% 4) Adjusted EPS Growth N/A 26% Double Digit Expansion Proof of Performance & 2015 Goals *ROIC is defined as TTM adjusted OI divided by the sum of average debt and equity over a 5 quarter period Page 8 *Percentage of Specialty Platform revenue from products introduced in last five years 19.5% 46.5% 2006 Q2 2013 $20.3 $44.7 2006 TTM Q2'13 14.3% 31.1% 2006 Q2 2013 Research & Development Spending Specialty Platform Vitality Index Progression* Innovation Drives Earnings Growth ($ millions) Specialty Platform Gross Margin % Page 9 We are Experts in Polymer Science and Formulation  Polymer Science  Formulation  Chemistry  Processing Inputs  Base Resins  Additives  Modifiers  Colorants Specialized Polymer Materials, Services, and Solutions Expertise Satisfied Consumers PolyOne Customer Innovative Products & Services  Marketplace Demands  Performance Requirements  Value Drivers Page 10 Positioned for Strong Growth 2015 Target Rev: $5B Adj. EPS: $2.50 Assumptions • Operating margins in mid-range of 2015 targets • No global recession • No investment in incremental PP&S capacity • Completion of 2-3 midsize accretive acquisitions • Housing starts at 85% of 50 year norm by 2015 • Mid single digit revenue CAGR • Remain comfortably below 3X Net Debt / EBITDA Page 11 2012 Rev: $2.9B Adj.

Use of Non-GAAP Measures Page 3 -150.00% -50.00% 50.00% 150.00% 250.00% 350.00% PolyOne S&P 500 All time high of $34.47 December 9th, 2013 • 16 consecutive quarters of double digit EPS growth • 42% CAGR adjusted EPS expansion 2006-2012 • YTD stock price has increased 63% versus 27% growth in the S&P • More than six fold increase in market cap: $0.5b $3.3b Strategy and Execution Drive Results Page 4 The World’s Premier Provider of Specialized Polymer Materials, Services & Solutions Four Pillar Strategy Page 5 PP&S 15% Specialty 60% Distribution 25% 0.12 0.27 0.21 0.13 0.68 0.82 1.00 2.50 $0.00 $0.25 $0.50 $0.75 $1.00 $1.25 $1.50 $1.75 $2.00 $2.25 $2.50 2006 2007 2008 2009 2010* 2011* 2012* 2015 Target Ad ju st ed E ar ni ng s P er S ha re Appliance 6% Building & Construction 13% Wire & Cable 9% Electrical & Electronics 4% Consumer 9% Packaging 18% Industrial 10% Misc. 5% HealthCare 9% Transportation 16% Textiles 1% United States 70% Europe 14% Canada 8% Asia 5% Latin America 3% 2012 Revenues: $4.0 Billion* End Markets* 2012 Revenues: $4.0 Billion* EPS Page 6 * Pro Forma includes FY2012 results for Spartech (11/03/12 YE) and Glasforms & excludes discontinued operations PolyOne At A Glance * Restated to exclude discontinued operations Old PolyOne Transformation *Operating Income excludes corporate charges and special items 2% 34% 43% 63% 65- 75% 0% 20% 40% 60% 80% 100% 2005 2008 2010 YTD 2013 2015 % o f O pe ra tin g In co m e* JV's PP&S Distribution Specialty Specialty OI $5M $46M $87M $153M Target Mix Shift Highlights Specialty Transformation 2015 Target Page 7 2006 YTD 2013 2015 Where we were Where we are Organic Consolidated Target 1) Operating Income % Specialty: Global Color, Additives & Inks 1.7% 12.8% 12.8% 12 – 16% Global Specialty Engineered Materials 1.1% 10.8% 8.9% 12 – 16% Designed Structures & Solutions — — 5.0% 8 – 10% Performance Products & Solutions 5.5% 8.0% 8.2% 9 – 12% Distribution 2.6% 6.1% 6 – 7.5% 2) Specialty Platform % of Operating Income 6.0% 63% 65 – 75% 3) ROIC* (after-tax) 5.0% 9.4% 15% 4) Adjusted EPS Growth N/A 28% Double Digit Expansion Proof of Performance & 2015 Goals *ROIC is defined as TTM adjusted OI divided by the sum of average debt and equity over a 5 quarter period Page 8 *Percentage of Specialty Platform revenue from products introduced in last five years 19.5% 44.0% 2006 Q3 2013 $20.3 $46.6 2006 TTM Q3'13 14.3% 31.0% 2006 Q3 2013 Research & Development Spending Specialty Platform Vitality Index Progression* Innovation Drives Earnings Growth ($ millions) Specialty Platform Gross Margin % Page 9 We are Experts in Polymer Science and Formulation  Polymer Science  Formulation  Chemistry  Processing Inputs  Base Resins  Additives  Modifiers  Colorants Specialized Polymer Materials, Services, and Solutions Expertise Satisfied Consumers PolyOne Customer Innovative Products & Services  Marketplace Demands  Performance Requirements  Value Drivers Page 10 Positioned for Strong Growth 2015 Target Rev: $5B Adj. EPS: $2.50 Assumptions • Mid single digit revenue CAGR • Operating margins in mid-range of 2015 targets • No global recession • No investment in incremental PP&S capacity • Housing starts at 85% of 50 year norm by 2015 • Remain comfortably below 3X Net Debt / EBITDA Page 11 2012 Rev: $2.9B Adj.